Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Recruiting · Phase 1 · NCT06062745
Conditions: Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
At a glance
- Research payments reported, 2025
- $40,526
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- Brigham and Women's Hospital (with Blue Earth Diagnostics)
- Tested
- 18F-fluciclovine (drug), PET/CT (device)
- Dates
- Started 2024-02-01; completion 2028-09-01
- Results posted
- Not yet
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA) expression or has neuroendocrine features. The name of the study interventions are: * 18F-fluciclovine-PET/CT scan * Two research blood collections
From ClinicalTrials.gov, last updated 2026-10-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blue Earth Diagnostics reported $40,526 in research payments for this study in 2025 (8 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $40,526
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.